CRYZL2P

Across TCGA pan-cancer cohorts, CRYZL2P Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CRYZL2P data layer compared with 23 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher CRYZL2P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRYZL2P expression acts as an unfavorable survival marker.

SARC and UCEC are the cancer types where CRYZL2P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.175	0.745	.007	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CRYZL2P–SARC (OS)

Open the SARC breakdown →